A delay in returning its Lotus Edge Aortic Valve System to the market has cost Boston Scientific an estimated $3B loss in market capitalization.
Source: BioSpace
A delay in returning its Lotus Edge Aortic Valve System to the market has cost Boston Scientific an estimated $3B loss in market capitalization.
Source: BioSpace